Table 1.
Patient demographics.
| Characteristics | Total |
|---|---|
| Age | 55.93 (30–83) |
| OP | |
| Hysterectomy | 7 (3.8%) |
| Hys+BSO | 19 (10.4%) |
| Hys+BSO+LD | 157 (85.8%) |
| Histologic type | |
| Endometrioid | 166 (90.7%) |
| Non-endometrioid | 17 (9.3%) |
| Histologic grade | |
| Low | 146 (79.8%) |
| High | 37 (20.2%) |
| LVSI | |
| Absent | 152 (83.1%) |
| Present | 31 (16.9%) |
| Myometrial invasion | |
| <50% | 145 (79.2%) |
| >50% | 38 (20.8%) |
| FIGO stage 2009 | |
| IA | 133 (72.7%) |
| IB | 33 (18.0%) |
| II | 15 (8.2%) |
| III | 2 (1.1%) |
| FIGO stage updated 2023 | |
| IA | 109 (59.6%) |
| IB | 18 (9.8%) |
| IC | 8 (4.4%) |
| IIA | 9 (4.9%) |
| IIB | 10 (5.5%) |
| IIC | 29 (15.8%) |
| Prognostic risk group * | |
| Low | 100 (54.6%) |
| Intermediate | 20 (10.9%) |
| High intermediate | 47 (25.7%) |
| High | 16 (8.8%) |
| Advanced | 0 (0.0%) |
| Adjuvant treatment | |
| None | 147 (80.3%) |
| Radiotherapy | 25 (13.7%) |
| Chemotherapy | 7 (3.8%) |
| Chemoradiotherapy | 4 (2.2%) |
| Recur/Distant meta | |
| Absent | 160 (87.4%) |
| Present | 20 (10.9%) |
| NA | 3 (1.6%) |
BSO, bilateral salpingo-oophorectomy; LD, lymph node dissection; LVSI, lymphovascular space invasion; FIGO, International Federation of Gynecology and Obstetrics; * risk stratified according to the 2016 ESMO/ESTRO/ESGO consensus guidelines.